| Overview |
| bs-11580R-Cy5.5 |
| RAI3 Polyclonal Antibody, Cy5.5 Conjugated |
| FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human RAI3 |
| 1-33/357 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cytoplasm, Cell membrane |
| G protein coupled receptor family C group 5 member A; G-protein coupled receptor family C group 5 member A; GPCR 5A; GPCR5A; Gprc 5a; Gprc5a; Orphan G protein coupling receptor PEIG 1; Orphan G protein coupling receptor PEIG1; Orphan G-protein-coupling receptor PEIG-1; RAI 3; RAI3_HUMAN; Raig 1; RAIG-1; Raig1; Retinoic acid induced 3; Retinoic acid induced gene 1 protein; Retinoic acid induced protein 3; Retinoic acid responsive; Retinoic acid responsive gene; Retinoic acid-induced gene 1 protein; Retinoic acid-induced protein 3. |
| RAI3 is an transmembrane G-protein-coupled receptor that affects many essential biological processes including embryogenesis, cell growth, differentiation, and apoptosis. RAI3 may also be involved in maintaining homeostasis of epithelial cells. Retinoic acid receptors directly regulate RAI3 during its transcription in embryonal carcinoma differentiation. RAI3 expression is upregulated in most tumor cell lines that express mutant p53, suggesting that p53 interacts with the promoter of RAI3 and represses its expression at the beginning of apoptosis. RAI3 is a potential molecular target for diagnosing breast cancer, and selective suppression of signals from RAI3 may have a place in breast cancer treatments. |
| Application Dilution |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz